Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00019) | |||||
---|---|---|---|---|---|
Name |
Aliskiren
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Aliskiren; 173334-57-1; Rasilez; Tekturna; SPP100; SPP 100; Aliskiren(CGP 60536); Enviage; Riprazo; Sprimeo; UNII-502FWN4Q32; Aliskiren fumarate; CHEMBL1639; CHEBI:601027; 502FWN4Q32; CGP 60536; (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-AMINO-N-(2-CARBAMOYL-2-METHYLPROPYL)-4-HYDROXY-2-ISOPROPYL-7-[4-METHOXY-3-(3-METHOXYPROPOXY)BENZYL]-8-METHYLNONANAMIDE; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis-(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; SPP-100; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; NCGC00186464-01; 173334-58-2; Aliskiren [USAN:INN:BAN]; CGP60536B; HSDB 7843; C30H53N3O6; (2s,4s,5s,7s)-5-amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide; (2S,4S,5S,7S)-5-amino-N-[2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide; CGP-060536B; Rasilez (TN); Aliskiren (USAN/INN); SCHEMBL455490; GTPL4812; BDBM17950; DTXSID40891494; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; ALBB-027274; EBD49928; ZINC4393164; MFCD09839018; STL386835; AKOS015852572; AKOS015888741; CS-0443; DB09026; MCULE-6209020635; NCGC00186464-02; 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate; HY-12176; SBI-0206888.P001; AB0015554; A11616; D03208; Q-4363; AB01274865-01; AB01274865_02; AB01274865_03; 334A582; Q414904; BRD-K30020243-051-01-7; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl)-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxo-propyl)-4-hydroxy-2-isopropyl-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-nonanamide; (2s,4s,5s,7s)-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide; 1327153-71-8; 5(S)-Amino-4(S)-hydroxy-2(S),7(S)-diisopropyl-8-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-octanoic acid N-(2-carbamoyl-2,2-dimethyl-ethyl)-amide; benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-, fumarate
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Essential hypertension | ICD-11: BA00 | [1] | ||
PubChem CID | |||||
Formula |
C30H53N3O6
|
||||
Canonical SMILES |
CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
|
||||
InChI |
1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1
|
||||
InChIKey |
UXOWGYHJODZGMF-QORCZRPOSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5493444"></iframe>
|
||||
3D MOL is unavailable | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 551.8 | Topological Polar Surface Area | 146 | |
XlogP | 3.5 | Complexity | 717 | ||
Heavy Atom Count | 39 | Rotatable Bond Count | 19 | ||
Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 7 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Aliskiren Hemifumarate eq 150mg base tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Crospovidone; Magnesium Stearate; Microcrystalline Cellulose; Povidone; Silica; Colloidal Anhydrous; Hypromellose; Macrogol; Talc; Iron Oxide, Black (E172); Iron Oxide, Red (E172); Titanium Dioxide (E171)
|
|||||
Dosage Form | Tablet | |||||
Company | Noden Pharma | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [2] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Polyethylene glycol 4000 | DIG Info | Albendazole monooxygenase (Inhibition ratio < 40 %) | [4] | |||
Aliskiren Hemifumarate eq 300mg base tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Crospovidone; Magnesium Stearate; Microcrystalline Cellulose; Povidone; Silica; Colloidal Anhydrous; Hypromellose; Macrogol; Talc; Iron Oxide, Black (E172); Iron Oxide, Red (E172); Titanium Dioxide (E171)
|
|||||
Dosage Form | Tablet | |||||
Company | Noden Pharma | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [2] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Polyethylene glycol 4000 | DIG Info | Albendazole monooxygenase (Inhibition ratio < 40 %) | [4] | |||
Aliskiren Hemifumarate eq 37.5mg base capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Basic Butylated Methacrylate Copolymer; Basic Colloidal Silicon Dioxide; Crospovidone; Povi Done; Dibutyl Sebacate; Magnesium Stearate; Microcrystalline Cellulose; Sodium Lauryl Sulphate
|
|||||
Dosage Form | Capsule | |||||
Company | Noden Pharma | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [5] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Aliskiren 150 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Talc; Titanium dioxide; Crospovidone; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Avera McKennan Hospital; Noden Pharma USA; Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Talc; Titanium dioxide; Crospovidone; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycol; Silicon dioxide, colloidal
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Physicians Total Care | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Aliskiren 300 mg tablet | Click to Show/Hide the Full List of Formulation(s): 3 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Talc; Titanium dioxide; Crospovidone; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | A-S Medication Solutions; Noden Pharma USA; Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Talc; Titanium dioxide; Crospovidone; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycol; Silicon dioxide, colloidal
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Physicians Total Care | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Drug Formulation 3 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Talc; Titanium dioxide; Silicon dioxide; Crospovidone (15 mpa.s at 5%); Hypromellose, unspecified; Microcrystalline cellulose; Polyethylene glycol, unspecified
|
|||||
Dosage Form | Oral Tablet | |||||
Company | A-S Medication Solutions | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.